G. Steven Burrill

Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.

Life-sciences companies continue upward momentum in 2014.

Frenzy cools as investors seeking a quick return turn elsewhere.

Early-stage companies are now embraced by buyers of new issues.

Biotech companies raise most money in 13 years.

Early-stage companies are finding alternatives to venture capital.

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

Collaborative R&D models coincide with new ways to fund translational research.

Better news about the global economy buoys life-sciences funding.